TY - JOUR T1 - DNA Methylation Architecture of the <em>ACE2</em> gene in Nasal Cells JF - medRxiv DO - 10.1101/2020.08.25.20182105 SP - 2020.08.25.20182105 AU - Andres Cardenas AU - Sheryl L. Rifas-Shiman AU - Joanne E. Sordillo AU - Dawn L. DeMeo AU - Andrea A Baccarelli AU - Marie-France Hivert AU - Diane R Gold AU - Emily Oken Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/16/2020.08.25.20182105.abstract N2 - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to the global coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2 enters cells via angiotensin-Converting Enzyme 2 (ACE2) receptors, highly expressed in nasal epithelium with parallel high infectivity.1,2 The nasal epigenome is in direct contact with the environment and could explain COVID-19 disparities by reflecting social and environmental influences on ACE2 regulation. We collected nasal swabs from anterior nares of 547 children, measured DNA methylation (DNAm), and tested differences at 15 ACE2 CpGs by sex, age, race/ethnicity and epigenetic age. ACE2 CpGs were differentially methylated by sex with 12 sites having lower DNAm (mean=12.71%) and 3 sites greater DNAm (mean=1.45%) among females relative to males. We observed differential DNAm at 5 CpGs for Hispanic females (mean absolute difference=3.22%) and lower DNAm at 8 CpGs for Black males (mean absolute difference=1.33%), relative to white participants. Longer DNAm telomere length was associated with greater ACE2 DNAm at 11 and 13 CpGs among males (mean absolute difference=7.86%) and females (mean absolute difference=8.21%), respectively. Nasal ACE2 DNAm differences could contribute to our understanding COVID-19 severity and disparities reflecting upstream environmental and social influences.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02820402Funding StatementThis work was supported by the US National Institutes of Health grants R01ES031259, R01HD034568 and UH3OD023286.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Harvard Pilgrim Health Care reviewed and approved all study protocols.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data to generate figures and tables are available from the corresponding author with the appropriate permission from the Project Viva study team and investigators (project_viva{at}hphc.org) upon reasonable request and institutional review board approval. ER -